References
- Leonard JP, Waldburger KE & Goldman SJ. Regulation of experi-mental autoimmune encephalomyelitis by interleukin-12. Ann NY Acad Sci 1996;795: 216–26.
- Constantinescu CS, Wysocka M, Hilliard B, Ventura ES, Lavi E, Trinchieri G, et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998;161:5097–104.
- Segal BM, Dwyer BK & Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187: 537–46.
- Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23 rather than interleukin-12 is the critical cyto-kine for autoimmune inflammation of the brain. Nature 2003;421: 744–8.
- Murphy CA, Langrish CL, Chen Yi, Blumenschein W, McCla-nahan T, Kastelein RA, et al. Divergent Pro- and Antiinflamma-tory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation. J Exp Med 2003;198: 1951–7.
- Hochberg MC. Updating the American College of Ftheumatology revised criteria for the classification of systemic lupus erythemato-sus [letter]. Arthritis Rheum 1997;40:1725.
- Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythema-tosus disease activity index 2000. J Ftheumatol 2002;29: 288–91.
- Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimula-tory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170(3):827–45.
- Trinchieri G, Wysocka M, D'Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res. 1992;4(4):355–68.
- Gran B, Zhang GX, Yu S, Li Jf, Chen XH, Ventura ES, et al. IL-12p35-Deficient Mice Are Susceptible to Experimental Autoim-mune Encephalomyelitis: Evidence for Redundancy in the IL-12 System in the Induction of Central Nervous System Autoimmune Demyelination. J Immunol 2002;169:7104–10.
- Oppmann B, Lesley R, Blom B, Timans JC, Xu YM, Hunte B, et al. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12. Immunity 2000;13:715–25.
- Lee VE, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis. J Exp Med 2004;199(4125–30.
- Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Thl-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Ftheumatol 1998;27:219–24.
- Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I, Powell RJ. Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8(-) and CD8(+) T cells in systemic lupus erythematosus. J Autoimmun 2001;17(2): 155–63.
- Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Trans-plantation. 2005 Oct 15;80(2 Suppl):5181–90.
- Kuzmanova SI. The macrophage activation syndrome: a new enti-ty, a potentially fatal complication of rheumatic disorders. Folia Med (Plovdiv). 2005;47(421–5.
- Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Taka-sald Y, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Thl- and Th2-derived cy-tokines. C lin Exp Immunol 1999;116(1):169–73.